The ever-expanding role of HIF in tumour and stromal biology

Nature Cell Biology

Volumn 18, Issue 4, 2016, Pages 356-365

  LaGory, Edward L ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; MESSENGER RNA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; CELL METABOLISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; METABOLITE; MITOCHONDRION; NEUTROPHIL; NONHUMAN; PARACRINE SIGNALING; PERICYTE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIUM; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84978695867     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3330     Document Type: Review

References (150)

1. Vaupel, P., & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast. Rev. 26, 225-239 (2007
2. Nagy, J. A., Chang, S. H., Dvorak, A. M., & Dvorak, H. F. Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 100, 865-869 (2009
3. Hanahan, D., & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012
4. Finger, E. C., & Giaccia, A. J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metast. Rev. 29, 285-293 (2010
5. Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47-71 (2014
6. Wiesener, M. S., et al. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 17, 271-273 (2003
7. Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995
8. Robinson, C. M., & Ohh, M. The multifaceted Von Hippel-Lindau tumour suppressor protein. FEBS Lett. 588, 2704-2711 (2014
9. Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 95, 7987-7992 (1998
10. Gossage, L., Eisen, T., & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55-64 (2015
11. Coleman, M. L., & Ratcliffe, P. J. Signalling cross talk of the HIF system: involvement of the FIH protein. Curr. Pharm. Design 15, 3904-3907 (2009
12. Hudson, C. C., et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002
13. Zhong, H., et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000
14. Duvel, K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010
15. Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. Jr TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158 (2003
16. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D., & Sillaber, C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100, 3767-3775 (2002
17. Faubert, B., et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc. Natl Acad. Sci. USA 111, 2554-2559 (2014
18. Shackelford, D. B., et al. mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl Acad. Sci. USA 106, 11137-11142 (2009
19. El-Naggar, A. M., et al. Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell 27, 682-697 (2015
20. Chou, C. C., Chuang, H. C., Salunke, S. B., Kulp, S. K., & Chen, C. S. A novel HIF- 1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells. Oncotarget 6, 8271-8285 (2015
21. Nakamura, H., et al. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 174, 7592-7599 (2005
22. Chisolm, D. A., & Weinmann, A. S. TCR-signaling events in cellular metabolism and specialization. Front. Immunol. 6, 292 (2015
23. Dang, E. V., et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 146, 772-784 (2011
24. Noman, M. Z., et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J. Immunol. 182, 3510-3521 (2009
25. Rius, J., et al. NF-?B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807-811 (2008
26. Blouin, C. C., Page, E. L., Soucy, G. M., & Richard, D. E. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1α. Blood 103, 1124-1130 (2004
27. Jantsch, J., et al. Toll-like receptor activation and hypoxia use distinct signaling pathways to stabilize hypoxia-inducible factor 1α (HIF1A) and result in differential HIF1A-dependent gene expression. J. Leukocyte Biol. 90, 551-562 (2011
28. Kurokawa, H., et al. High resolution imaging of intracellular oxygen concentration by phosphorescence lifetime. Sci. Rep. 5, 10657 (2015
29. Gong, Y., & Agani, F. H. Oligomycin inhibits HIF-1α expression in hypoxic tumor cells. Am. J. Physiol. Cell Physiol. 288, C1023-C1029 (2005
30. O'Hagan, K. A., et al. PGC-1α is coupled to HIF-1α-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc. Natl Acad. Sci. USA 106, 2188-2193 (2009
31. Yan, M., et al. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J. Clin. Invest. 124, 2640-2650 (2014
32. LaGory, E. L., et al. Suppression of PGC-1α is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep. 12, 116-127 (2015
33. Trachootham, D., Alexandre, J., & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 8, 579-591 (2009
34. Niecknig, H., et al. Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia. Free Radical Res. 46, 705-717 (2012
35. Bell, E. L., & Chandel, N. S. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 43, 17-27 (2007
36. Mansfield, K. D., et al. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab. 1, 393-399 (2005
37. Chandel, N. S., et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA 95, 11715-11720 (1998
38. Masson, N., et al. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep. 13, 251-257 (2012
39. Hagen, T. Oxygen versus reactive oxygen in the regulation of HIF-1α: the balance tips. Biochem. Res. Int. 2012, 436981 (2012
40. Pollard, P. J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005
41. Lu, H., et al. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 280, 41928-41939 (2005
42. Reitman, Z. J., & Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl Cancer Inst. 102, 932-941 (2010
43. Ye, D., Ma, S., Xiong, Y., & Guan, K. L. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 23, 274-276 (2013
44. Wong, B. W., Kuchnio, A., Bruning, U., & Carmeliet, P. Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. Trends Biochem. Sci. 38, 3-11 (2013
45. Zhang, D., et al. Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation. Cell Rep. 10, 1335-1348 (2015
46. Zeng, L., et al. Aberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis. Oncogene 34, 4758-4766 (2015
47. Li, B., et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513, 251-255 (2014
48. Luo, W., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744 (2011
49. Gao, X., Wang, H., Yang, J. J., Liu, X., & Liu, Z. R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598-609 (2012
50. Nakajima, E. C., & Van Houten, B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol. Carcinogen. 52, 329-337 (2013
51. Peppicelli, S., Bianchini, F., & Calorini, L. Extracellular acidity, a "reappreciated" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. Cancer Metast. Rev. 33, 823-832 (2014
52. Wang, T., Liu, G., & Wang, R. The intercellular metabolic interplay between tumor and immune cells. Front. Immunol. 5, 358 (2014
53. Ho, P. C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217-1228 (2015
54. Chang, C. H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241 (2015
55. Folkman, J. Proceedings: tumor angiogenesis factor. Cancer Res. 34, 2109-2113 (1974
56. Franses, J. W., Baker, A. B., Chitalia, V. C., & Edelman, E. R. Stromal endothelial cells directly influence cancer progression. Sci. Transl. Med. 3, 66ra5 (2011
57. Coulon, C., et al. From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscl. Throm. Vas. Biol. 30, 2331-2336 (2010
58. Polet, F., & Feron, O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J. Intern. Med. 273, 156-165 (2013
59. Schoors, S., et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192-197 (2015
60. Huang, D., et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep. 8, 1930-1942 (2014
61. el Azzouzi, H., et al. The hypoxia-inducible microRNA cluster miR-199a~214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation. Cell. Metab. 18, 341-354 (2013
62. Krishnan, J., et al. Dietary obesity-associated HIF1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Gene. Dev. 26, 259-270 (2012
63. Rankin, E. B., et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 29, 4527-4538 (2009
64. Tang, N., et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6, 485-495 (2004
65. Skuli, N., et al. Endothelial deletion of hypoxia-inducible factor-2α (HIF-2α) alters vascular function and tumor angiogenesis. Blood 114, 469-477 (2009
66. Skuli, N., et al. Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J. Clin. Invest. 122, 1427-1443 (2012
67. Mazzone, M., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009
68. Branco-Price, C., et al. Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell 21, 52-65 (2012
69. Carmeliet, P., & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011
70. Morikawa, S., et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000 (2002
71. Greenberg, J. I., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813 (2008
72. Cooke, V. G., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-81 (2012
73. Keskin, D., et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep. 10, 1066-1081 (2015
74. Vasudev, N. S., & Reynolds, A. R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494 (2014
75. Maione, F., et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 122, 1832-1848 (2012
76. Sounni, N. E., et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20, 280-294 (2014
77. Bensaad, K., et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9, 349-365 (2014
78. Tong, R. T., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004
79. Winkler, F., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004
80. Kalluri, R., & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006
81. Bochet, L., et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73, 5657-5668 (2013
82. Hinz, B., et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816 (2007
83. Direkze, N. C., et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64, 8492-8495 (2004
84. Gilkes, D. M., Semenza, G. L., & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430-439 (2014
85. Kim, J. W., et al. Loss of fibroblast HIF-1α accelerates tumorigenesis. Cancer Res. 72, 3187-3195 (2012
86. Madsen, C. D., et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep. 16, 1394-1408 (2015
87. Kuchnio, A., et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. Cell Rep. 12, 992-1005 (2015
88. Cirri, P., & Chiarugi, P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1, 482-497 (2011
89. Pavlides, S., et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984-4001 (2009
90. Martinez-Outschoorn, U. E., Lisanti, M. P., & Sotgia, F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25, 47-60 (2014
91. Chiavarina, B., et al. Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 11, 3280-3289 (2012
92. Sonveaux, P., et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE 7, e33418 (2012
93. Sonveaux, P., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942 (2008
94. Fiaschi, T., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 72, 5130-5140 (2012
95. Costa, A., Scholer-Dahirel, A., & Mechta-Grigoriou, F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin. Cancer Biol. 25, 23-32 (2014
96. Orimo, A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005
97. Schioppa, T., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198, 1391-1402 (2003
98. Ammirante, M., Shalapour, S., Kang, Y., Jamieson, C. A., & Karin, M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc. Natl Acad. Sci. USA 111, 14776-14781 (2014
99. Schito, L., et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl Acad. Sci. USA 109, E2707-E2716 (2012
100. Caniggia, I., et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGF?3. J. Clin. Invest. 105, 577-587 (2000
101. Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (2004
102. Bronte, V., & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641-654 (2005
103. Ino, Y., et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE 8, e55146 (2013
104. Baginska, J., et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl Acad. Sci. USA 110, 17450-17455 (2013
105. Du, R., et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220 (2008
106. Sitkovsky, M., & Lukashev, D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nat. Rev. Immunol. 5, 712-721 (2005
107. Mamlouk, S., et al. Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. Int. J. Cancer 134, 849-858 (2014
108. Bingle, L., Brown, N. J., & Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002
109. Qian, B. Z., & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51 (2010
110. Casazza, A., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/ Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695-709 (2013
111. Murdoch, C., Giannoudis, A., & Lewis, C. E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234 (2004
112. Matschurat, S., et al. Regulation of EMAP II by hypoxia. Am. J. Pathol. 162, 93-103 (2003
113. Wen, Z., et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene 34, 1241-1252 (2015
114. Rolny, C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44 (2011
115. Klug, F., et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/ M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589-602 (2013
116. Laoui, D., et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74, 24-30 (2014
117. Takeda, N., et al. Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis. Gene. Dev. 24, 491-501 (2010
118. Cramer, T., et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003
119. Imtiyaz, H. Z., et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699-2714 (2010
120. Doedens, A. L., et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475 (2010
121. Colegio, O. R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559-563 (2014
122. Lu, H., Forbes, R. A., & Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277, 23111-23115 (2002
123. Goodwin, M. L., et al. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. Cancer Cell 26, 851-862 (2014
124. Stockmann, C., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-818 (2008
125. Corzo, C. A., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453 (2010
126. Noman, M. Z., et al. Tumor promoting effects of myeloid derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res. 75, 3771-3787 (2015
127. Sceneay, J., et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906-3911 (2012
128. Cox, T. R., et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522, 106-110 (2015
129. Erler, J. T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006
130. Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519-531 (2011
131. Yoshida, N., et al. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am. J. Physiol. 262, H1891-H1898 (1992
132. Blaisdell, A., et al. Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell 28, 785-799 (2015
133. Walmsley, S. R., et al. Hypoxia-induced neutrophil survival is mediated by HIF-1α- dependent NF-?B activity. J. Exp. Med. 201, 105-115 (2005
134. Liang, W., & Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 4, 83-91 (2016
135. Fridlender, Z. G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-?: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009
136. Le, Q. T., et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol. 23, 8932-8941 (2005
137. Viguier, M., et al. Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453 (2004
138. Facciabene, A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475, 226-230 (2011
139. Synnestvedt, K., et al. Ecto-5-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993-1002 (2002
140. Ohta, A., et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132-13137 (2006
141. Lee, J. H., Elly, C., Park, Y., & Liu, Y. C. E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory T cell stability and suppressive capacity. Immunity 42, 1062-1074 (2015
142. Bailey, S. R., et al. Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5, 276 (2014
143. Ben-Shoshan, J., Maysel-Auslender, S., Mor, A., Keren, G., & George, J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1α. Eur. J. Immunol. 38, 2412-2418 (2008
144. Clambey, E. T., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl Acad. Sci. USA 109, E2784-E2793 (2012
145. Shi, L. Z., et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367-1376 (2011
146. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
147. Noman, M. Z., et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790 (2014
148. Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 74, 665-674 (2014
149. Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. Structural integration in hypoxia-inducible factors. Nature 524, 303-308 (2015
150. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003